Lacking markers for HER2, Estrogen or Progesterone receptors that strongly suggest that there is benefit of targeted therapy, triple negative breast cancer (TNBC) is looked upon by clinicians as a “bad tumor” with high recurrence rate in spite of adjuvant chemotherapy. Here, ERBB2 is linked to neoplasm.